Literature DB >> 14552754

Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties.

Yasutsugu Ueda1, John D Matiskella, Jerzy Golik, Timothy P Connolly, Thomas W Hudyma, Srini Venkatesh, Mandar Dali, Shin-Hong Kang, Nancy Barbour, Ravi Tejwani, Sailesh Varia, Jay Knipe, Ming Zheng, Marina Mathew, Kathy Mosure, Junius Clark, Lucinda Lamb, Ivette Medin, Qi Gao, Stella Huang, Chung-Pin Chen, Joanne J Bronson.   

Abstract

Synthesis of phosphonooxymethyl derivatives of ravuconazole, 2 (BMS-379224) and 3 (BMS-315801) and their biological evaluation as potential water-soluble prodrugs of ravuconazole are described. The phosphonooxymethyl ether analogue 2 (BMS-379224) and N-phosphonooxymethyl triazolium salt 3 (BMS-315801) were both prepared from ravuconazole (1) and bis-tert-butyl chloromethylphosphate, but under two different conditions. Both derivatives were highly soluble in water and converted to the parent in alkaline phosphatase, and also in vivo (rat). However, BMS-315801 was found to be less stable than BMS-379224 in water at neutral pH. BMS-379224 (2) has proved to be one of the most promising prodrugs of ravuconazole that we tested, and it is currently in clinical evaluation as an intravenous formulation of the broad spectrum antifungal azole, ravuconazole.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552754     DOI: 10.1016/j.bmcl.2003.08.029

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  VNI cures acute and chronic experimental Chagas disease.

Authors:  Fernando Villalta; Mark C Dobish; Pius N Nde; Yulia Y Kleshchenko; Tatiana Y Hargrove; Candice A Johnson; Michael R Waterman; Jeffrey N Johnston; Galina I Lepesheva
Journal:  J Infect Dis       Date:  2013-01-31       Impact factor: 5.226

2.  Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity.

Authors:  Pollyanna Álvaro Spósito; Ana Lia Mazzeti; Caroline de Oliveira Faria; Julio A Urbina; Gwenaelle Pound-Lana; Maria Terezinha Bahia; Vanessa Furtado Mosqueira
Journal:  Int J Nanomedicine       Date:  2017-05-17

3.  Novel phenolic antimicrobials enhanced activity of iminodiacetate prodrugs against biofilm and planktonic bacteria.

Authors:  Danica J Walsh; Tom Livinghouse; Greg M Durling; Adrienne D Arnold; Whitney Brasier; Luke Berry; Darla M Goeres; Philip S Stewart
Journal:  Chem Biol Drug Des       Date:  2020-09-22       Impact factor: 2.817

Review 4.  Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition.

Authors:  Yen-Ting Lai
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

5.  Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts.

Authors:  Satish Patil; Lev G Lis; Robert J Schumacher; Beverly J Norris; Monique L Morgan; Rebecca A D Cuellar; Bruce R Blazar; Raj Suryanarayanan; Vadim J Gurvich; Gunda I Georg
Journal:  J Med Chem       Date:  2015-11-24       Impact factor: 7.446

Review 6.  Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.

Authors:  Tao Wang; John F Kadow; Nicholas A Meanwell
Journal:  Med Chem Res       Date:  2021-09-28       Impact factor: 1.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.